Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Zelenetz, Andrew D, Prof, Barrientos, Jacqueline C, MD, Brown, Jennifer R, MD, Coiffier, Bertrand, Prof, Delgado, Julio, MD, Egyed, Miklós, Prof, Ghia, Paolo, MD, Illés, Árpád, Prof, Jurczak, Wojciech, MD, Marlton, Paula, MBBS, Montillo, Marco, MD, Morschhauser, Franck, Prof, Pristupa, Alexander S, MD, Robak, Tadeusz, Prof, Sharman, Jeff P, MD, Simpson, David, MBChB, Smolej, Lukáš, MD, Tausch, Eugen, MD, Adewoye, Adeboye H, MD, Dreiling, Lyndah K, MD, Kim, Yeonhee, PhD, Stilgenbauer, Stephan, Prof, Hillmen, Peter, Prof
Published in The lancet oncology (01.03.2017)
Published in The lancet oncology (01.03.2017)
Get full text
Journal Article
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
van Oers, Marinus H J, Prof, Kuliczkowski, Kazimierz, Prof, Smolej, Lukáš, MD, Petrini, Mario, Prof, Offner, Fritz, Prof, Grosicki, Sebastian, MD, Levin, Mark-David, MD, Gupta, Ira, MD, Phillips, Jennifer, PhD, Williams, Vanessa, MS, Manson, Stephanie, PhD, Lisby, Steen, MD, Geisler, Christian, Prof
Published in The lancet oncology (01.10.2015)
Published in The lancet oncology (01.10.2015)
Get full text
Journal Article